Registered Nurse

Tenet's expansion into Conifer and outpatient growth: The true driver of earnings overlooked amid insider selling distractions. By: 101 finance Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now! Insider activity and leadership changes: context for Tenet Healthcare. Recent developments at Tenet Healthcare have drawn attention, particularly regarding insider transactions and changes in leadership. Paola Arbour, the company's Chief Information Officer, sold 18,168 shares in March 2024, bringing her total sales over the past year to 56,724 shares, with no corresponding purchases. This activity followed the departure of board member Stephen H. Rusckowski in November 2025. These events together highlight a trend of insider selling and boardroom turnover. For investors, the main question is whether these actions are significant indicators or simply background noise. The market has had time to process both the executive's share sales and the board change, with the CIO's transactions occurring more than a year ago and the board resignation announced last fall. During this period, Tenet has been undergoing a substantial strategic transformation, including the $2.4 billion divestiture of three South Carolina hospitals in early 2024 as part of a broader shift in its business portfolio. The company has also rapidly expanded its ambulatory care network, adding more than 50 new surgery centers within a year. Given these broader changes, market sentiment appears to be focused on Tenet's strategic direction rather than individual leadership exits. The company's recent price-to-earnings ratio of 17.28, which is below the sector median, suggests that investors are prioritizing operational execution and business transformation over management turnover. While insider selling is noteworthy, it may simply reflect routine financial planning or diversification by a long-serving executive, especially in the context of a company actively reinventing itself. Ultimately, expectations are being shaped by Tenet's strategic initiatives. The company's share price likely already factors in the reality of ongoing transformation. The real challenge lies not in executive departures, but in whether Tenet can continue to deliver on its ambitious plans. So far, the market seems to have absorbed the impact of leadership changes into the larger narrative of corporate evolution. Strategic portfolio realignment: the main value catalyst. While much attention has been paid to changes in Tenet's leadership, the real story lies in the company's disciplined approach to capital allocation and business restructuring. The major transactions completed in 2024 and 2026 are part of a cohesive strategy to strengthen Tenet's hospital and ambulatory platforms by divesting lower-margin assets and regaining control of essential services. * 2024 Hospital Sale: The $2.4 billion sale of three South Carolina hospitals to Novant Health marked a pivotal step in Tenet's transformation, as the company divested a total of 14 hospitals that year. The transaction provided a substantial cash boost to reduce debt and strengthen the balance sheet, despite resulting in a $222 million annual EBITDA reduction. The trade-off was considered worthwhile for the increased financial flexibility and streamlined operations. * 2026 Conifer Acquisition: In early 2026, Tenet finalized an agreement with CommonSpirit Health to acquire full ownership of Conifer Health Solutions. This $1.9 billion deal, which included payments and a capital redemption, eliminated a redeemable non-controlling interest and $885 million in liabilities. Gaining full control of Conifer enables Tenet to better integrate revenue cycle management with its operational objectives and invest in future growth. These strategic moves have fueled Tenet's expansion in ambulatory care. By the end of 2024, its United Surgical Partners International subsidiary had grown from 461 to 518 ambulatory surgery centers, adding 57 new facilities in just one year. This shift from traditional hospital operations to higher-margin outpatient care is the primary driver of value. Leadership changes, in this context, are secondary to the company's fundamental transformation, which is already reflected in its market valuation. Strategy spotlight: absolute momentum long-only approach. Tenet's stock performance has also been analyzed using a long-only absolute momentum strategy. This approach involves entering positions when the 252-day rate of change is positive and the closing price is above the 200-day simple moving average, and exiting when the price falls below the 200-day average, after 20 trading days, or upon reaching a take-profit of 8% or a stop-loss of 4%. The backtest, covering April 2024 to April 2026, yielded the following results: * Total Return: 26.91% * Annualized Return: 15.07% * Maximum Drawdown: 17.81% * Profit-Loss Ratio: 1.43 * Win Rate: 47.83% (11 wins out of 23 trades) * Average Holding Period: 8.87 days Financial performance and earnings outlook. Tenet's investment appeal is closely tied to its ability to deliver on financial targets. The company has a history of meeting or exceeding its own guidance, as demonstrated in January 2023 when it announced it would surpass the midpoint of its FY22 Adjusted EBITDA forecast. This track record of operational discipline is now under scrutiny as Tenet works to translate its strategic changes into sustainable earnings growth. The upcoming earnings report on April 30 will be a critical milestone, offering the first comprehensive look at the financial impact of the 2024 hospital divestitures and the 2026 Conifer acquisition. Investors will be watching to see if the rapid expansion of ambulatory services is beginning to offset the EBITDA lost from hospital sales and drive top-line growth. The market will be looking for evidence that Tenet can maintain its momentum as it pivots toward outpatient care. This sets up a classic risk/reward scenario. While the company's strategic moves are already priced into the stock, the true test will be Tenet's ability to convert its growing ambulatory platform and prudent capital management into consistent earnings growth. With the stock trading below the industry median, any failure to meet or exceed expectations could prompt a market reassessment. For now, Tenet is viewed as a capable operator meeting high expectations, but the upcoming earnings release will be a key indicator of whether it can sustain this performance. Key catalysts and risks: beyond executive departures. Looking ahead, Tenet's outlook is shaped by two main factors: a significant financial catalyst and ongoing governance risks. The most immediate catalyst is the execution of the Conifer transaction, which is structured as a multi-year arrangement. The deal, completed in early 2026, involves approximately $1.9 billion in payments from CommonSpirit to Tenet over three years. While this provides a steady cash flow, the real challenge will be how effectively management uses these funds to support further ambulatory expansion and reduce debt, ultimately driving sustained earnings growth. However, the ongoing pattern of insider selling remains a concern. Over the past year, there have been seven insider sales and no insider purchases, which could be interpreted as a lack of internal confidence. While the CIO's sales are not recent, continued insider selling or further leadership changes could raise questions about the company's strategic direction and financial health, potentially testing the market's current optimism. Ultimately, Tenet's future performance will depend on its ability to deliver sustained earnings growth as it scales its outpatient business and manages its substantial debt. The Conifer payments provide a financial buffer, but operational excellence remains essential. The upcoming earnings report will offer crucial insight into how these strategic initiatives are affecting the bottom line. In this environment, the impact of individual executive departures is overshadowed by the tangible financial outcomes of Tenet's multi-year transformation and the ongoing question of whether insider selling signals deeper concerns. Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Guggenheim has raised its price target on Tenet Healthcare Corporation from $271 to $283, maintaining a Buy rating on the stock. The firm cited the company's 90% return and described the first quarter as an "easy set-up" due to conservative guidance. It also views the projected 10% core EBITDA growth for 2026 as achievable. On the same day, Mizuho increased its price target from $235 to $265, maintaining an Outperform rating. The firm expects Tenet Healthcare to benefit from demographic shifts toward an ageing population and a focus on higher-acuity surgeries. Founded in 1969, Tenet Healthcare is a Texas-based diversified healthcare services company operating through Hospital Operations and Ambulatory Care segments.